Capital Advisors Ltd’s Actinium Pharmaceuticals ATNM Stock Holding History

Capital Advisors Ltd’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-63	Closed	–	–	1364
2024 Q3	$0	Buy	+63	New	+$249	﹤0.01%	1361

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Capital Advisors Ltd's ATNM Position: Q4 2024 in Review

Capital Advisors Ltd sold out of Actinium Pharmaceuticals (ATNM) in Q4 2024, closing a stake of 63 shares.

Capital Advisors Ltd first reported a position in ATNM in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 69 funds tracked by Wall St. Rank hold ATNM as of Q4 2024.

Capital Advisors Ltd reported no remaining Actinium Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Capital Advisors Ltd sold 63 Actinium Pharmaceuticals shares in Q4 2024.
Capital Advisors Ltd first reported a position in Actinium Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Capital Advisors Ltd's Actinium Pharmaceuticals position peaked at $0 in Q3 2024.
69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2024.

Based on Capital Advisors Ltd's 13F filing for Q4 2024, filed 4 Feb 2025.